There is provided herein the molecule that glycosylated BTLA (B and T lymphocyte decay factor) is selectively combined relative to the BTLA being not glycosylated, such as antibody. Additionally provide the method for manufacturing and using such molecule, the method including treating or diagnosing cancer. In some embodiments, anti-glycosylation BTLA antibody provided herein can immunospecifically combine glycosylated wild type BTLA (WT). In some embodiments, anti-glycosylation BTLA antibody provided herein can combine one or more BTLA double-mutants with immunologic specificity, only remain the single glycosylation site at BTLA N75, N94 or N110. In some embodiments, for the BTLA Trimutants of no N75, N94 or N110-O glycosylation site for retaining BTLA, anti-glycosylation BTLA antibody provided herein only shows background combination, if combination.
